Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
Recruiting · NCT05758493 · Registry updated 2026-04-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis | Nutritional and Metabolic Diseases, amyloidosis, familial amyloid neuropathy, metabolic disease, proteostasis deficiencies | Recruiting | Phase 2 | 2026-04-13 | NCT05758493 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Attralus, Inc. | 3 |
| Bayer | 178 |
| Oregon Health and Science University | 244 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Oregon Health & Science University | Portland | United States | 261 |